Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Should Be Excluded From Guideline Development – NEJM Editorial

Executive Summary

Standards for the development and adoption of treatment guidelines should be established in light of efforts by industry to manipulate guidelines for commercial purposes, NIH Critical Care Medicine Department senior investigators assert

You may also be interested in...



Attempts To Rein In Drug Reps Should Consider Physician Specialty, Setting

Guidelines directed at the interaction of sales representatives and physicians should be tailored to medical specialties and settings, according to an analysis of a physician survey published in the April 26 New England Journal of Medicine

Attempts To Rein In Drug Reps Should Consider Physician Specialty, Setting

Guidelines directed at the interaction of sales representatives and physicians should be tailored to medical specialties and settings, according to an analysis of a physician survey published in the April 26 New England Journal of Medicine

Industry CME Affiliates Would Be Restricted Under Accrediting Proposal

Continuing medical education providers affiliated with drug manufacturers would be prohibited from conducting CME programs in therapeutic categories where the manufacturer has products under a proposed revision to the Accreditation Council for Continuing Medical Education's standards for providers

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel